choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Ofatumumab

Ofatumumab Newsletter
  • DoP Shortlists Patented, Unlaunched Drugs for Global Tender Exemption, See Full List 26 Nov 2025 21:17 GMT

    … Council of Medical Research (ICMR), several central procurement bodies, and pharmaceutical industry … contest the inclusion of any drug by demonstrating local manufacturing capability … Gelatin Capsule 150 Mg 21. Ofatumumab 20 mg/0.4 …

  • Follicular Lymphoma Treatment Market to Grow at 8.1% CAGR from 2025-2029 24 Nov 2025 09:30 GMT

    … and Johnson Services Inc. • GlaxoSmithKline plc • Novartis AG • Merck … States biotech firm Genentech Inc. obtained FDA approval … of fixed-duration cancer treatment immunotherapies, and it … Antibodies: Rituximab, Obinutuzumab, Ofatumumab 2) By Targeted …

  • DoP mulls exemption of 84 more drugs from public procurement rules that restrict global tender 25 Nov 2025 06:34 GMT

    … General Armed Forces Medical Services (DGAFMS). The … by Amgen, and cancer treatment drugs such as Venetoclax … The proprietary drugs under this part include ofatumumab 20 … Shingrix from Glaxo SmithKline Pharmaceuticals, rheumatoid arthritis drug Simponi from …

  • Multiple sclerosis: three trials to watch 28 Oct 2025 11:28 GMT

    … treatment paradigm.” Christie Wong, managing neurology analyst at GlobalData, seconds this, stating … led OVERLORD-MS trial (NCT04578639) trial, rituximab is being … back in trials, as she thought the drug had “ … Ocrevus or Kesimpta (ofatumumab) in the general …

  • Novartis' new drugs outweigh Entresto decline in Q3 28 Oct 2025 14:05 GMT

    … cancer radiotherapy Pluvicto (177Lu vipivotide), Kesimpta (ofatumumab) for multiple sclerosis, and leukaemia drug … Narasimhan also highlighted the recent FDA approval of Rhapsido (remibrutinib) … assets with pipeline-in-a-pill potential that could underpin …

  • Novartis Q3: new drugs step up as generics squeeze Entresto 28 Oct 2025 15:39 GMT

    … Multiple sclerosis treatment Kesimpta (ofatumumab) also contributed … disorder treatment Promacta (eltrombopag) and blood cancer drug Tasigna … Avidity Biosciences, a biotech developing RNA therapeutics. … deserve! The Pharmaceutical Technology Excellence Awards …

  • <![CDATA[Future Directions and Trial Design Needs in MS]]> 05 Oct 2025 20:26 GMT

    … Spain, new findings on ofatumumab (Kesimpta; Novartis) drew … rigorous data on sequencing, treatment spacing, discontinuation strategies, … underscores how innovative trial design can address the … may differ. Innovative trials like ARTIOS are essential …

  • <![CDATA[Evolving Role of Ofatumumab Since Approval]]> 04 Oct 2025 23:44 GMT

    … Spain, new findings on ofatumumab (Kesimpta; Novartis) drew … results from the ARTIOS trial, which evaluated patients switching … MS treatment research. Since its 2020 FDA approval, ofatumumab has … studies—both randomized clinical trials and real-world data …

  • <![CDATA[Comparing Mechanisms and Advantages of MS Medication Ofatumamab]]> 02 Oct 2025 23:57 GMT

    … were results from the ARTIOS trial, which evaluated patients switching from … -term treatment planning. Transcript is edited for clarity. Riley Bove: Ofatumumab is … a B-cell–depleting medication. It’s a …

  • <![CDATA[Overviewing Phase 3 ARTIOS Findings on Ofatumumab]]> 03 Oct 2025 17:42 GMT

    … European Committee for Treatment and Research in Multiple … Spain, new findings on ofatumumab (Kesimpta; Novartis) drew significant … results from the ARTIOS trial, which evaluated patients … fingolimod or fumarate-based medications but had recent MRI …

Satisfied with the content?

Continue to create your account.